Distinct prognostic values ofp53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers

Takahashi, Masato; Tonoki, Hidefumi; Tada, Mitsuhiro; Kashiwazaki, Haruhiko; Furuuchi, Keiji; Hamada, Jun Ichi; Fujioka, Yasunori; Sato, Yuji; Takahashi, Hiromasa; Todo, Satoru; Sakuragi, Noriaki; Moriuchi, Tetsuya

doi:10.1002/(sici)1097-0215(20000120)89:1<92::aid-ijc15>3.0.co;2-8

Cited by 30 publications

(16 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…25,29,31,32 In the present study, cases 13, 27, and 28, which showed 15% red colonies, contained no clonal mutations. All of the other cases, which had more red colonies, contained clonal p53 mutations.…”

Section: Discussionsupporting

confidence: 45%

Loss of p53 transcriptional activity in hepatocellular carcinoma evaluated by yeast-based functional assay: comparison with p53 immunohistochemistry

et al. 2004

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 45%

Loss of p53 transcriptional activity in hepatocellular carcinoma evaluated by yeast-based functional assay: comparison with p53 immunohistochemistry

et al. 2004

Self Cite

View full text Add to dashboard Cite

“…In contrast, no expression of both receptors was shown in MCF-7 cells that carried wild-type p53 and positive estrogen receptor. Given that p53 mutation and loss of estrogen receptor are poor prognostic indicators (38), coexpression of RON and MET seems to signify an invasive phenotype for breast cancer cells.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Significance of Co-expression of RON and MET Receptors in Node-Negative Breast Cancer Patients

Lee

Chen

Chow

et al. 2005

Clinical Cancer Research

127

116

View full text Add to dashboard Cite

Purpose: RON and MET belong to a subfamily of tyrosine kinase receptors. They both can induce invasive growth, including migration, cell dissociation, and matrix invasion. Cross-linking experiments show that RON and MET form a noncovalent complex on the cell surface and cooperate in intracellular signaling. We wanted to examine the clinical significance of RON and MET expression patterns in node-negative breast cancer.Experimental Design: We studied the protein expressions of RON and MET in five breast cancer cell lines and a homogeneous cohort of 103 T 1-2 N 0 M 0 breast carcinoma patients, including 52 patients with distant metastases and 51 patients with no evidence of disease after at least a 10-year follow-up.Results: Both HCC1937 and MDA-MB-231 cancer cell lines co-overexpressed RON and MET. The MCF-7 cell line did not express RON or MET. In multiple logistic regression analysis, RON expression (odds ratio, 2.6; P = 0.05) and MET expression (odds ratio, 4.7; P = 0.009) were independent predictors of distant relapse. RON+ +/MET+ + and RONÀ À/ MET+ tumors resulted in a large risk increase for 10-year disease-free survival after adjusting for tumor size, histologic grade, estrogen receptor, bcl-2, HER-2/neu, and p53 status by multivariate Cox analysis (risk ratio, 5.3; P = 0.001 and risk ratio, 3.76; P = 0.005). The 10-year disease-free survival was 79.3% in patients with RONÀ À/METÀ À tumors, was only 11.8% in patients with RON+ +/MET+ + tumors, and was 43.9% and 55.6% in patients with RONÀ/MET+ + and RON+ +/ METÀ À tumors.Conclusions: Co-expression of RON and MET seems to signify an aggressive phenotype in node-negative breast cancer patients.

show abstract

“…More than 200 colonies were examined on each culture plate and the average percentage of red colonies was determined. In this assay system, more than 16% red colonies were judged as positive for p53 mutation [14].…”

Section: Yeast P53 Functional Assaymentioning

confidence: 99%

p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells

Dong

Tada

Hamada

et al. 2007

Clin Exp Metastasis

Self Cite

View full text Add to dashboard Cite

Distinct prognostic values ofp53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers

Cited by 30 publications

References 22 publications

Loss of p53 transcriptional activity in hepatocellular carcinoma evaluated by yeast-based functional assay: comparison with p53 immunohistochemistry

Loss of p53 transcriptional activity in hepatocellular carcinoma evaluated by yeast-based functional assay: comparison with p53 immunohistochemistry

Prognostic Significance of Co-expression of RON and MET Receptors in Node-Negative Breast Cancer Patients

p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells

Contact Info

Product

Resources

About